ログイン

RODAKS HEMATOLOGY

RODAKS HEMATOLOGY
100問 • 1年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    Hb Bart is composed of: a. Two alpha and two beta chains b. Two epsilon and two gamma chains c. Four beta chains d. Four gamma chains

    d. Four gamma chains

  • 2

    The stage in neutrophilic development in which the nucleus is indented in a kidney bean shape and the cytoplasm has secondary granules that are lavender in color a. Band c. Promyelocyte b. Myelocyte d. Metamyelocyte

    d. Metamyelocyte

  • 3

    Which of the following cells are important in immune regulation, allergic inflammation, and destruction of tissue invading helminths? a. Neutrophils and monocytes b. Eosinophils and basophils c. T and B lymphocytes

    b. Eosinophils and basophils

  • 4

    Macrophages aid in adaptive immunity by: a. Degrading antigen and presenting it to lymphocytes b. Ingesting and digesting organisms that neutrophils cannot c. Synthesizing complement components d. Storing iron from senescent red cells

    a. Degrading antigen and presenting it to lymphocytes

  • 5

    . Using Wright-Giemsa stain, the morphologic description of an eccentric dark nuclei with deeply basophilic (blue) cytoplasm and a prominent pale central Golgi apparatus best describes a(n): a. Eosinophil c. Lymphocyte b. Basophil d. Plasma cell

    d. Plasma cell

  • 6

    Which of the following inherited leukocyte disorders is caused by a mutation in the lamin B receptor? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d. May-Hegglin anomaly

    a. Pelger-Huët anomaly

  • 7

    Which of the following inherited leukocyte disorders involves mutations in nonmuscle myosin heavy-chain IIA? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d.. May-Hegglin anomaly

    d.. May-Hegglin anomaly

  • 8

    Which of the following inherited leukocyte disorders might be seen in Hurler syndrome? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d. May-Hegglin anomaly

    c. Alder-Reilly anomaly

  • 9

    Which of the following lysosomal storage diseases is charac- terized by macrophages with striated cytoplasm and storage of glucocerebroside? a. Sanfilippo syndrome c. Fabry disease b. Gaucher disease d. Niemann-Pick disease

    b. Gaucher disease

  • 10

    The neutrophils in chronic granulomatous disease are incapable of producing: a. Hydrogen peroxide c. Superoxide b. Hypochlorite d. All of the above

    d. All of the above

  • 11

    Individuals with X-linked SCID have a mutation that affects their ability to synthesize: a. Deaminase c. IL-2 receptor b. Oxidase d. IL-8 receptor

    c. IL-2 receptor

  • 12

    What leukocyte cytoplasmic inclusion is composed of ribosomal RNA? a. Primary granules c. Döhle bodies b. Toxic granules d. Howell-Jolly bodies

    c. Döhle bodies

  • 13

    Lymphomas differ from leukemias in that they are: a. Solid tumors b. Not considered systemic diseases c. Never found in peripheral blood d. Do not originate from hematopoietic cells

    a. Solid tumors

  • 14

    Which one of the following viruses is known to cause lymphoid neoplasms in humans? a. HIV-1 c. Hepatitis B b. HTLV-1 d. Parvovirus B

    b. HTLV-1

  • 15

    Loss-of-function of tumor suppressor genes increase the risk of hematologic neoplasms by: a. Suppressing cell division b. Activating tyrosine kinases which promote proliferation c. Promoting excessive apoptosis of hematopoietic cells d. Allowing cells with damaged DNA to progress through the cell cycle

    d. Allowing cells with damaged DNA to progress through the cell cycle

  • 16

    Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2

    Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2

  • 17

    Imatinib is an example of what type of treatment? a. Supportive care c. Bone marrow conditioning agent b. Chemotherapy d. Targeted therapy

    d. Targeted therapy

  • 18

    According to the WHO classification, except in leukemias with specific genetic anomalies, the minimal percentage of blasts for a diagnosis of acute leukemia is: a. 10% b. 20% c. 30% d. 50%

    b. 20%

  • 19

    SBB stains which of the following component of cells? a. Glycogen c. Structural proteins b. Lipids d. Enzymes

    b. Lipids

  • 20

    The cytochemical stain a-naphthyl butyrate is a nonspecific esterase stain that shows diffuse positivity in cells of which lineage? a. Erythroid c. Granulocytic b. Monocytic d. Lymphoid

    b. Monocytic

  • 21

    Disseminated intravascular coagulation is more often seen in association with leukemia characterized by which of the following mutations? a. t(12;21)(p13;q22) c. inv(16)(p13;q22) b. t(9;22)(q34;q11.2) d. t(15;17)(q22;q12)

    d. t(15;17)(q22;q12)

  • 22

    A 20-year-old patient has an elevated WBC count with 70% blasts, 4% neutrophils, 5% lymphocytes, and 21% monocytes in the peripheral blood. Eosinophils with dysplastic changes are seen in the bone marrow. AML with which of the following karyotypes would be most likely to be a. AML with t(8;21)(q22;q22) b. AML with t(16;16)(p13;q22) c. APL with PML-RARA d. AML with t(9;11)(p22;q23)

    b. AML with t(16;16)(p13;q22)

  • 23

    Which of the following leukemias affects primarily children, is characterized by an increase in monoblasts and monocytes, and often is associated with gingival and skin involvement? a. Pre-B-lymphoblastic leukemia b. Pure erythroid leukemia c. AML with t(9;11)(p22;q23) d. APL with PML-RARA

    c. AML with t(9;11)(p22;q23)

  • 24

    A 20-year-old patient presents with fatigue, pallor, easy bruising, and swollen gums. Bone marrow examination reveals 82% cells with delicate chromatin and prominent nucleoli that are CD14 , CD4 , CD11b , and CD36 . Which of the following acute leukemias is likely? a. Minimally differentiated leukemia b. Leukemia of ambiguous lineage c. Acute monoblastic/monocytic leukemia d. Acute megakaryoblastic leukemia

    c. Acute monoblastic/monocytic leukemia

  • 25

    Pure erythroid leukemia is a disorder involving: a. Pronormoblasts only b. Pronormoblasts and basophilic normoblasts c. All forms of developing RBC precursors d. Equal numbers of pronormoblasts and myeloblasts

    b. Pronormoblasts and basophilic normoblasts

  • 26

    A patient with normal chromosomes has a WBC count of 3.0 x 10^9/L and dysplasia in all cell lines. There are 60% blasts of varying sizes. The blasts stain positive for CD61. The most likely type of leukemia is: a. Acute lymphoblastic c. Acute monoblastic b. Acute megakaryoblastic d. APL with PML-RARA

    b. Acute megakaryoblastic

  • 27

    Which of the following chromosome abnormalities is associated with CML? a. t(15;17) c. t(9;22) b. t(8;14) d. Monosomy 7

    c. t(9;22)

  • 28

    A patient has a WBC count of 30 x 10^9 /L and the following WBC differential: Segmented neutrophils—38%. Bands—17% Metamyelocytes—7% Myelocytes—20% Promyelocytes—10% Eosinophils—3% Basophils—5% Which of the following test results would be helpful in determining whether the patient has CML? a. Nitroblue tetrazolium reduction product increased b. Myeloperoxidase increased c. Periodic acid–Schiff staining decreased d. FISH positive for BCR-ABL1 fusion

    d. FISH positive for BCR-ABL1 fusion

  • 29

    The most common mutation found in patients with primary PV is: a. BCR-ABL1 c. JAK2 V617F b. Philadelphia chromosome d. t(15;17)

    c. JAK2 V617F

  • 30

    The peripheral blood in PV typically manifests: a. Erythrocytosis only b. Erythrocytosis and thrombocytopenia c. Erythrocytosis, thrombocytosis, and granulocytosis d. Anemia and thrombocytopenia

    c. Erythrocytosis, thrombocytosis, and granulocytosis

  • 31

    Which of the following patterns is characteristic of the peripheral blood in patients with PMF? a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes b. Abnormal platelets only c. Hypochromic erythrocytes, immature granulocytes, and normal platelets d. Spherocytes, immature granulocytes, and increased numbers of platelets

    a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes

  • 32

    A patient has a platelet count of 700 x 10^9 /L with abnormalities in the size, shape, and granularity of platelets; a WBC count of 12 x 10^9 /L; and hemoglobin of 11 g/dL. The Philadelphia chromosome is not present. The most likely diagnosis is: a. PV c. CML b. ET d. Leukemoid reaction

    b. ET

  • 33

    What is a major indication of MDS in the peripheral blood and bone marrow? a. Dyspoiesis b. Leukocytosis with left shift c. Normal bone marrow with abnormal peripheral blood d. Thrombocytosis

    a. Dyspoiesis

  • 34

    In Hodgkin lymphoma the Reed-Sternberg cell and _________ are malignant. a. Popcorn cells c. B cells b. T cells d. Histiocytes

    a. Popcorn cells

  • 35

    What platelet membrane receptor binds fibrinogen and supports platelet aggregation? a. GP Ib/IX/V c. GP Ia/IIa b. GP IIb/IIIa d. P2Y1

    b. GP IIb/IIIa

  • 36

    What plasma protein is essential for platelet adhesion? a. VWF c. Fibrinogen b. Factor VIII d. P-selectin

    a. VWF

  • 37

    What platelet membrane phospholipid flips from the inner surface to the plasma surface on activation and serves as the assembly point for coagulation factors? a. Phosphatidylethanolamine c. Phosphatidylcholine b. Phosphatidylinositol d. Phosphatidylserine

    d. Phosphatidylserine

  • 38

    What platelet organelle sequesters ionic calcium and binds a series of enzymes of the eicosanoid pathway? a. Glycocalyx c. Dense tubular system b. Dense granules d. Surface connected canalicular system

    c. Dense tubular system

  • 39

    Which of the following molecules is stored in platelet dense granules? a. Serotonin c. Platelet factor 4 b. Fibrinogen d. Platelet-derived growth factor

    a. Serotonin

  • 40

    Which of the following molecules is stored in platelet dense granules? a. Serotonin c. Platelet factor 4 b. Fibrinogen d. Platelet-derived growth factor

    a. Serotonin

  • 41

    What is the name of the eicosanoid metabolite produced from endothelial cells that suppresses platelet activity? a. Thromboxane A2 c. Cyclooxygenase b. Arachidonic acid d. Prostacyclin

    d. Prostacyclin

  • 42

    White clots: a. Occur primarily in the deep veins of the leg b. Are characteristic of the secondary hemostatic process c. Are largely composed of platelets and VWF d. Form normally in response to vascular injury and are completely harmless

    c. Are largely composed of platelets and VWF

  • 43

    What intimal cell synthesizes and stores von Willebrand factor (VWF)? a. Smooth muscle cell c. Fibroblast b. Endothelial cell d. Platelet

    b. Endothelial cell

  • 44

    The events involved in secondary hemostasis: a. Lead to the formation of a stable fibrin clot b. Usually occur independently of primary hemostasis c. Occur in a random fashion d. Are the first line of defense against blood loss

    a. Lead to the formation of a stable fibrin clot

  • 45

    What subendothelial structural protein triggers coagulation through activation of factor VII? a. Thrombomodulin c. Tissue factor b. Nitric oxide d. Thrombin

    c. Tissue factor

  • 46

    What coagulation plasma protein should be assayed when platelets fail to aggregate properly? a. Factor VIII c. Thrombin b. Fibrinogen d. Factor X

    b. Fibrinogen

  • 47

    What is the primary role of vitamin K for the prothrombin group factors? a. Provides a surface on which the proteolytic reactions of the factors occur b. Protects them from inappropriate activation by compounds such as thrombin c. Accelerates the binding of the serine proteases and their cofactors d. Carboxylates the factors to allow calcium binding

    d. Carboxylates the factors to allow calcium binding

  • 48

    What two regulatory proteins form a complex that digests activated factors V and VIII? a. TFPI and Xa b. Antithrombin and protein C c. APC and protein S d. Thrombomodulin and plasmin

    c. APC and protein S

  • 49

    Which of the following coagulation factors is activated by thrombin and mediates the stabilization of the fibrin clot? a. Tissue factor c. Factor IX b. FactorVII d. Factor XIII

    d. Factor XIII

  • 50

    A defect in primary hemostasis (platelet response to an injury) often results in: a. Musculoskeletal bleeding c. Hemarthroses b. Mucosal bleeding d. None of the above

    b. Mucosal bleeding

  • 51

    The clinical presentation of platelet-related bleeding may include all of the following except: a. Bruising c. Gastrointestinal bleeding b. Nosebleeds. d. Bleeding into the joints (hemarthroses)

    d. Bleeding into the joints (hemarthroses)

  • 52

    A defect in GP IIb/IIIa causes: a. Glanzmann thrombasthenia c. Gray platelet syndrome b. Bernard-Soulier syndrome d. Storage pool disease

    a. Glanzmann thrombasthenia

  • 53

    Patients with Bernard-Soulier syndrome have which of the following laboratory test findings? a. Abnormal platelet response to arachidonic acid b. Abnormal platelet response to ristocetin c. Abnormal platelet response to collagen d. Thrombocytosis

    b. Abnormal platelet response to ristocetin

  • 54

    Aspirin ingestion blocks the synthesis of: a. Thromboxane A2 c. Collagen b. Ionized calcium d. ADP

    a. Thromboxane A2

  • 55

    What factor becomes deficient early in liver disease, and what assay does its deficiency prolong? a. Prothrombin deficiency, the PT b. Factor VII deficiency, the PT c. FVIII deficiency, the PTT d. Factor IX deficiency, the PTT

    b. Factor VII deficiency, the PT

  • 56

    Which of the following conditions causes a prolonged thrombin time? a. Antithrombin deficiency c. Hypofibrinogenemia b. Prothrombin deficiency d. Warfarin therapy

    c. Hypofibrinogenemia

  • 57

    What is the most prevalent form of VWD? a. Type1 c. Type 2B b. Type 2A d.Type3

    a. Type1

  • 58

    In what type or subtype of VWD is the RIPA test result positive when ristocetin is used at a concentration of less than 0.5 mg/mL? a. Subtype 2A c. Subtype 2N b. Subtype 2B d. Type 3

    b. Subtype 2B

  • 59

    What is the typical treatment for vitamin K deficiency when the patient is bleeding? a. Vitamin K and plasma b. Vitamin K and four-factor PCC c. Vitamin K and platelet concentrate d. Vitamin K and FVIII concentrate

    b. Vitamin K and four-factor PCC

  • 60

    If a patient has anatomic soft tissue bleeding and poor wound healing, but the PT, PTT, TT, platelet count, and platelet functional assay results are normal, what factor deficiency is possible? a. Fibrinogen c. Factor XII b. Prothrombin d. Factor XIII

    d. Factor XIII

  • 61

    What therapy may be used for a hemophilic boy who is bleeding and who has a high FVIII inhibitor titer? a. rFVIIa c. Cryoprecipitate b. Plasma d. FVIII concentrate

    a. rFVIIa

  • 62

    Which of the following assays is used to distinguish vitamin K deficiency from liver disease? a. PT c. Factor V assay b. Protein C assay d. Factor VII assay

    c. Factor V assay

  • 63

    What is the most common heritable thrombosis risk factor? a. APC resistance (factor V Leiden mutation) b. Prothrombin G20210A mutation c. Antithrombin deficiency d. Protein S deficiency

    a. APC resistance (factor V Leiden mutation)

  • 64

    In most LAC profiles, what test is primary (performed first) because it detects LAC with the least interference? a. Low-phospholipid PTT c. KCT b. DRVVT d. PT

    b. DRVVT

  • 65

    A 1:20 dilution of blood is made with 3% glacial acetic acid as the diluent. The four large corner squares on both sides of the hemacytometer are counted, for a total of 100 cells. What is the total WBC count (x 10^9 /L)? a. 0.25 b. 2.5 c. 5 d. 10

    b. 2.5

  • 66

    The total WBC count is 20 x 10^9/L. Twenty-five NRBCs per 100 WBCs are observed on the peripheral blood film. What is the corrected WBC count (x 10^9/L)? a. 0.8 b. 8 c. 16 d. 19

    c. 16

  • 67

    Which of the following would NOT interfere with the result when hemoglobin determination is performed by the cyanmethemoglobin method? a. Increased lipids c. Lyse-resistant RBCs b. Elevated WBC count d. Fetal hemoglobin

    d. Fetal hemoglobin

  • 68

    A patient has a hemoglobin level of 8.0 g/dL. According to the rule of three, what is the expected range for the HCT? a. 21% to 24% c. 24% to 27% b. 23.7% to 24.3% d. 21% to 27%

    d. 21% to 27%

  • 69

    Given the following values, calculate the RPI: Observed reticulocyte count = 6% HCT = 30% a. 2 c. 4 b.3 d.5

    a. 2

  • 70

    Which of the following would be associated with an elevated ESR value? a. Microcytosis c. Decreased globulins b. Polycythemia d. Inflammation

    d. Inflammation

  • 71

    A laboratory science student consistently makes wedgetechnique blood films that are too long and thin. What change in technique would improve the films? a. Increasing the downward pressure on the pusher slide b. Decreasing the acute angle of the pusher slide c. Placing the drop of blood closer to the center of the slide d. Increasing the acute angle of the pusher slide

    d. Increasing the acute angle of the pusher slide

  • 72

    When a blood film is viewed through the microscope, the RBCs appear redder than normal, the neutrophils are barely visible, and the eosinophils are bright orange. What is the most likely cause? a. The slide was overstained. b. The stain was too alkaline. c. The buffer was too acidic. d. The slide was not rinsed adequately.

    c. The buffer was too acidic

  • 73

    A stained blood film is held up to the light and observed to be bluer than normal. What microscopic abnormality might be expected on this film? a. Rouleaux c. Reactive lymphocytosis b. Spherocytosis d. Toxic granulation

    a. Rouleaux

  • 74

    A laboratorian using the 40x objective lens sees the following numbers of WBCs in 10 fields: 8,4,7,5,4,7,8,6,4,6. Which of the following WBC counts most closely correlates with the estimate? a. 1.5 x 10^9/L c. 11.8 x 10^9/L b. 5.9 x 10^9/L d. 24 x 10^9/L

    c. 11.8 x 10^9/L

  • 75

    A blood film for a patient with a normal RBC count has an average of 10 platelets per oil immersion field. Which of the following values best correlates with the estimate per microliter? a. 20,000 c. 200,000 b. 100,000 d. 400,000

    c. 200,000

  • 76

    A blood film for a very anemic patient with an RBC count of 1.25 x 10^12/L shows an average of seven platelets per oil immersion field. Which of the following values most closely correlates with the estimate per microliter? a. 14,000 c. 140,000 b. 44,000 d. 280,000

    b. 44,000

  • 77

    Which of the following blood film findings indicates EDTAinduced pseudothrombocytopenia? a. The platelets are pushed to the feathered end. b. The platelets are adhering to WBCs. c. No platelets at all are seen on the film. d. The slide has a bluish discoloration when examined macroscopically

    b. The platelets are adhering to WBCs.

  • 78

    Orthogonal light scatter is used to measure: a. Cell volume b. Internal complexity of the cell c. Cellular granularity d. Nuclear density

    b. Internal complexity of the cell

  • 79

    A patient peripheral blood film demonstrates agglutinated RBCs, and the CBC shows an elevated MCHC. What other parameters will be affected by the agglutination of the RBCs? a. MCV will be decreased and RBC count will be increased. b. MCV will be decreased and RBC count will be decreased. c. MCV will be increased and RBC count will be decreased. d. MCV will be increased and RBC count will be increased.

    c. MCV will be increased and RBC count will be decreased.

  • 80

    On the Beckman Coulter instruments, hematocrit is a calculated value. Which of the following directly measured parameters is used in the calculation of this value? a. RDW c. MCV b. Hemoglobin d. MCHC

    c. MCV

  • 81

    What is the most common clinical application of flow cytometry? a. Diagnosis of platelet disorders b. Detection of fetomaternal hemorrhage c. Diagnosis of leukemias and lymphomas d. Differentiation of anemias

    c. Diagnosis of leukemias and lymphomas

  • 82

    Which of the following is true of CD45 antigen? a. It is present on every cell subpopulation in the bone marrow. b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors. c. It is not measured routinely in flow cytometry. d. It may be present on nonhematopoietic cells.

    b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors

  • 83

    Erythroid precursors are characterized by the expression of: a. CD71 b. CD20 c. CD61 d. CD3

    a. CD71

  • 84

    Antigens expressed by B-LL include: a. CD3, CD4, and CD8 b. CD19, CD34, and CD10 c. There are no antigens specific for B-LL. d. Myeloperoxidase

    b. CD19, CD34, and CD10

  • 85

    Which of the following is true of flow cytometric gating? a. It is best defined as selection of a target population for flow cytometric analysis. b. It can be done only at the time of data acquisition. c. It can be done only at the time of final analysis and interpretation of flow cytometric data. d. It is accomplished by adjusting flow rate

    a. It is best defined as selection of a target population for flow cytometric analysis

  • 86

    Mycosis fungoides is characterized by: a. Loss of certain antigens compared with the normal T cell population b. Polyclonal T cell receptor c. Immunophenotype indistinguishable from that of normal T cells d. Expression of CD3 and CD8 antigens

    a. Loss of certain antigens compared with the normal T cell population

  • 87

    Mature granulocytes show the expression of: a. CD15, CD33, and CD34 b. CD15, CD33, and CD41 c. CD15, CD33, and CD13 d. CD15, CD33, and CD7

    c. CD15, CD33, and CD13

  • 88

    What happens if a coagulation specimen collection tube is underfilled? a. The specimen clots and is useless b. The specimen is hemolyzed and is useless c. Clot-based test results are falsely prolonged d. Chromogenic test results are falsely decreased

    c. Clot-based test results are falsely prolonged

  • 89

    What is the reference method for detecting aspirin or clopidogrel resistance? a. Platelet aggregometry c. VerifyNow b. AspirinWorks d. PFA-100

    a. Platelet aggregometry

  • 90

    Except for platelet aggregometry, most coagulation testing must be performed on PPP, which is plasma with a platelet count less than: a. 1000/uL c. 100,000/uL b. 10,000/uL d. 1,000,000/uL

    b. 10,000/uL

  • 91

    You wish to obtain a 5-mL specimen of whole-blood/ anticoagulant mixture. The patient’s hematocrit is 65%. What volume of anticoagulant should you use? a. 0.32 mL c. 0.64 mL b. 0.5 mL d. 0.68 mL

    a. 0.32 mL

  • 92

    You perform whole-blood lumiaggregometry on a specimen from a patient who complains of easy bruising. Aggregation and secretion are diminished when the agonists thrombin, ADP, arachidonic acid, and collagen are used. What is the most likely platelet abnormality? a. Storage pool disorder c. ADP receptor anomaly b. Aspirin-like syndrome d. Glanzmann thrombasthenia

    d. Glanzmann thrombasthenia

  • 93

    What is the reference assay for HIT? a. Enzyme immunoassay c. Platelet lumiaggregometry b. Serotonin release assay d. Washed platelet aggregation

    b. Serotonin release assay

  • 94

    What agonist is used in platelet aggregometry to detect VWD? a. Arachidonic acid c. Collagen b. Ristocetin d. ADP

    b. Ristocetin

  • 95

    Deficiency of which congenital single factor is likely when the PT result is prolonged and the PTT result is normal? a. FactorV c. FactorVIII b. Factor VII d. Prothrombin

    b. Factor VII

  • 96

    A prolonged PT, a low factor VII level, but a normal factor V level are characteristic of an acquired coagulopathy associated with which of the following? a. Vitamin K deficiency c. Liver disease b. Thrombocytopenia d. Hemophilia

    a. Vitamin K deficiency

  • 97

    The patient has deep vein thrombosis. The PTT is prolonged and is not corrected in an immediate mix of patient PPP with an equal part of PNP. What is the presumed condition? a. Factor VIII inhibitor c. Factor VIII deficiency b. Lupus anticoagulant d. Factor V Leiden mutation

    b. Lupus anticoagulant

  • 98

    What condition causes the most pronounced elevation in the result of the quantitative D-dimer assay? a. Deep vein thrombosis c. Paraproteinemia b. Fibrinogen deficiency d. DIC

    d. DIC

  • 99

    When a specimen has been flagged as being icteric by an automated coagulation analyzer, which method would be most susceptible to erroneous results because of the interfering substance? a. Mechanical clot detection b. Immunologic antigen-antibody reaction detection c. Photo-optical clot detection d. Chromogenic end-point detection

    c. Photo-optical clot detection

  • 100

    Which of the following is considered to be an advantage of the mechanical end-point detection methodology? a. It is not affected by lipemia in the test specimen b. It has the ability to provide a graph of clot formation c. It can incorporate multiple wavelengths into a single testing sequence d. It can measure proteins that do not have fibrin formation as the end-point

    a. It is not affected by lipemia in the test specimen

  • other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    Hb Bart is composed of: a. Two alpha and two beta chains b. Two epsilon and two gamma chains c. Four beta chains d. Four gamma chains

    d. Four gamma chains

  • 2

    The stage in neutrophilic development in which the nucleus is indented in a kidney bean shape and the cytoplasm has secondary granules that are lavender in color a. Band c. Promyelocyte b. Myelocyte d. Metamyelocyte

    d. Metamyelocyte

  • 3

    Which of the following cells are important in immune regulation, allergic inflammation, and destruction of tissue invading helminths? a. Neutrophils and monocytes b. Eosinophils and basophils c. T and B lymphocytes

    b. Eosinophils and basophils

  • 4

    Macrophages aid in adaptive immunity by: a. Degrading antigen and presenting it to lymphocytes b. Ingesting and digesting organisms that neutrophils cannot c. Synthesizing complement components d. Storing iron from senescent red cells

    a. Degrading antigen and presenting it to lymphocytes

  • 5

    . Using Wright-Giemsa stain, the morphologic description of an eccentric dark nuclei with deeply basophilic (blue) cytoplasm and a prominent pale central Golgi apparatus best describes a(n): a. Eosinophil c. Lymphocyte b. Basophil d. Plasma cell

    d. Plasma cell

  • 6

    Which of the following inherited leukocyte disorders is caused by a mutation in the lamin B receptor? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d. May-Hegglin anomaly

    a. Pelger-Huët anomaly

  • 7

    Which of the following inherited leukocyte disorders involves mutations in nonmuscle myosin heavy-chain IIA? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d.. May-Hegglin anomaly

    d.. May-Hegglin anomaly

  • 8

    Which of the following inherited leukocyte disorders might be seen in Hurler syndrome? a. Pelger-Huët anomaly c. Alder-Reilly anomaly b. Chédiak-Higashi disease d. May-Hegglin anomaly

    c. Alder-Reilly anomaly

  • 9

    Which of the following lysosomal storage diseases is charac- terized by macrophages with striated cytoplasm and storage of glucocerebroside? a. Sanfilippo syndrome c. Fabry disease b. Gaucher disease d. Niemann-Pick disease

    b. Gaucher disease

  • 10

    The neutrophils in chronic granulomatous disease are incapable of producing: a. Hydrogen peroxide c. Superoxide b. Hypochlorite d. All of the above

    d. All of the above

  • 11

    Individuals with X-linked SCID have a mutation that affects their ability to synthesize: a. Deaminase c. IL-2 receptor b. Oxidase d. IL-8 receptor

    c. IL-2 receptor

  • 12

    What leukocyte cytoplasmic inclusion is composed of ribosomal RNA? a. Primary granules c. Döhle bodies b. Toxic granules d. Howell-Jolly bodies

    c. Döhle bodies

  • 13

    Lymphomas differ from leukemias in that they are: a. Solid tumors b. Not considered systemic diseases c. Never found in peripheral blood d. Do not originate from hematopoietic cells

    a. Solid tumors

  • 14

    Which one of the following viruses is known to cause lymphoid neoplasms in humans? a. HIV-1 c. Hepatitis B b. HTLV-1 d. Parvovirus B

    b. HTLV-1

  • 15

    Loss-of-function of tumor suppressor genes increase the risk of hematologic neoplasms by: a. Suppressing cell division b. Activating tyrosine kinases which promote proliferation c. Promoting excessive apoptosis of hematopoietic cells d. Allowing cells with damaged DNA to progress through the cell cycle

    d. Allowing cells with damaged DNA to progress through the cell cycle

  • 16

    Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2

    Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2

  • 17

    Imatinib is an example of what type of treatment? a. Supportive care c. Bone marrow conditioning agent b. Chemotherapy d. Targeted therapy

    d. Targeted therapy

  • 18

    According to the WHO classification, except in leukemias with specific genetic anomalies, the minimal percentage of blasts for a diagnosis of acute leukemia is: a. 10% b. 20% c. 30% d. 50%

    b. 20%

  • 19

    SBB stains which of the following component of cells? a. Glycogen c. Structural proteins b. Lipids d. Enzymes

    b. Lipids

  • 20

    The cytochemical stain a-naphthyl butyrate is a nonspecific esterase stain that shows diffuse positivity in cells of which lineage? a. Erythroid c. Granulocytic b. Monocytic d. Lymphoid

    b. Monocytic

  • 21

    Disseminated intravascular coagulation is more often seen in association with leukemia characterized by which of the following mutations? a. t(12;21)(p13;q22) c. inv(16)(p13;q22) b. t(9;22)(q34;q11.2) d. t(15;17)(q22;q12)

    d. t(15;17)(q22;q12)

  • 22

    A 20-year-old patient has an elevated WBC count with 70% blasts, 4% neutrophils, 5% lymphocytes, and 21% monocytes in the peripheral blood. Eosinophils with dysplastic changes are seen in the bone marrow. AML with which of the following karyotypes would be most likely to be a. AML with t(8;21)(q22;q22) b. AML with t(16;16)(p13;q22) c. APL with PML-RARA d. AML with t(9;11)(p22;q23)

    b. AML with t(16;16)(p13;q22)

  • 23

    Which of the following leukemias affects primarily children, is characterized by an increase in monoblasts and monocytes, and often is associated with gingival and skin involvement? a. Pre-B-lymphoblastic leukemia b. Pure erythroid leukemia c. AML with t(9;11)(p22;q23) d. APL with PML-RARA

    c. AML with t(9;11)(p22;q23)

  • 24

    A 20-year-old patient presents with fatigue, pallor, easy bruising, and swollen gums. Bone marrow examination reveals 82% cells with delicate chromatin and prominent nucleoli that are CD14 , CD4 , CD11b , and CD36 . Which of the following acute leukemias is likely? a. Minimally differentiated leukemia b. Leukemia of ambiguous lineage c. Acute monoblastic/monocytic leukemia d. Acute megakaryoblastic leukemia

    c. Acute monoblastic/monocytic leukemia

  • 25

    Pure erythroid leukemia is a disorder involving: a. Pronormoblasts only b. Pronormoblasts and basophilic normoblasts c. All forms of developing RBC precursors d. Equal numbers of pronormoblasts and myeloblasts

    b. Pronormoblasts and basophilic normoblasts

  • 26

    A patient with normal chromosomes has a WBC count of 3.0 x 10^9/L and dysplasia in all cell lines. There are 60% blasts of varying sizes. The blasts stain positive for CD61. The most likely type of leukemia is: a. Acute lymphoblastic c. Acute monoblastic b. Acute megakaryoblastic d. APL with PML-RARA

    b. Acute megakaryoblastic

  • 27

    Which of the following chromosome abnormalities is associated with CML? a. t(15;17) c. t(9;22) b. t(8;14) d. Monosomy 7

    c. t(9;22)

  • 28

    A patient has a WBC count of 30 x 10^9 /L and the following WBC differential: Segmented neutrophils—38%. Bands—17% Metamyelocytes—7% Myelocytes—20% Promyelocytes—10% Eosinophils—3% Basophils—5% Which of the following test results would be helpful in determining whether the patient has CML? a. Nitroblue tetrazolium reduction product increased b. Myeloperoxidase increased c. Periodic acid–Schiff staining decreased d. FISH positive for BCR-ABL1 fusion

    d. FISH positive for BCR-ABL1 fusion

  • 29

    The most common mutation found in patients with primary PV is: a. BCR-ABL1 c. JAK2 V617F b. Philadelphia chromosome d. t(15;17)

    c. JAK2 V617F

  • 30

    The peripheral blood in PV typically manifests: a. Erythrocytosis only b. Erythrocytosis and thrombocytopenia c. Erythrocytosis, thrombocytosis, and granulocytosis d. Anemia and thrombocytopenia

    c. Erythrocytosis, thrombocytosis, and granulocytosis

  • 31

    Which of the following patterns is characteristic of the peripheral blood in patients with PMF? a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes b. Abnormal platelets only c. Hypochromic erythrocytes, immature granulocytes, and normal platelets d. Spherocytes, immature granulocytes, and increased numbers of platelets

    a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes

  • 32

    A patient has a platelet count of 700 x 10^9 /L with abnormalities in the size, shape, and granularity of platelets; a WBC count of 12 x 10^9 /L; and hemoglobin of 11 g/dL. The Philadelphia chromosome is not present. The most likely diagnosis is: a. PV c. CML b. ET d. Leukemoid reaction

    b. ET

  • 33

    What is a major indication of MDS in the peripheral blood and bone marrow? a. Dyspoiesis b. Leukocytosis with left shift c. Normal bone marrow with abnormal peripheral blood d. Thrombocytosis

    a. Dyspoiesis

  • 34

    In Hodgkin lymphoma the Reed-Sternberg cell and _________ are malignant. a. Popcorn cells c. B cells b. T cells d. Histiocytes

    a. Popcorn cells

  • 35

    What platelet membrane receptor binds fibrinogen and supports platelet aggregation? a. GP Ib/IX/V c. GP Ia/IIa b. GP IIb/IIIa d. P2Y1

    b. GP IIb/IIIa

  • 36

    What plasma protein is essential for platelet adhesion? a. VWF c. Fibrinogen b. Factor VIII d. P-selectin

    a. VWF

  • 37

    What platelet membrane phospholipid flips from the inner surface to the plasma surface on activation and serves as the assembly point for coagulation factors? a. Phosphatidylethanolamine c. Phosphatidylcholine b. Phosphatidylinositol d. Phosphatidylserine

    d. Phosphatidylserine

  • 38

    What platelet organelle sequesters ionic calcium and binds a series of enzymes of the eicosanoid pathway? a. Glycocalyx c. Dense tubular system b. Dense granules d. Surface connected canalicular system

    c. Dense tubular system

  • 39

    Which of the following molecules is stored in platelet dense granules? a. Serotonin c. Platelet factor 4 b. Fibrinogen d. Platelet-derived growth factor

    a. Serotonin

  • 40

    Which of the following molecules is stored in platelet dense granules? a. Serotonin c. Platelet factor 4 b. Fibrinogen d. Platelet-derived growth factor

    a. Serotonin

  • 41

    What is the name of the eicosanoid metabolite produced from endothelial cells that suppresses platelet activity? a. Thromboxane A2 c. Cyclooxygenase b. Arachidonic acid d. Prostacyclin

    d. Prostacyclin

  • 42

    White clots: a. Occur primarily in the deep veins of the leg b. Are characteristic of the secondary hemostatic process c. Are largely composed of platelets and VWF d. Form normally in response to vascular injury and are completely harmless

    c. Are largely composed of platelets and VWF

  • 43

    What intimal cell synthesizes and stores von Willebrand factor (VWF)? a. Smooth muscle cell c. Fibroblast b. Endothelial cell d. Platelet

    b. Endothelial cell

  • 44

    The events involved in secondary hemostasis: a. Lead to the formation of a stable fibrin clot b. Usually occur independently of primary hemostasis c. Occur in a random fashion d. Are the first line of defense against blood loss

    a. Lead to the formation of a stable fibrin clot

  • 45

    What subendothelial structural protein triggers coagulation through activation of factor VII? a. Thrombomodulin c. Tissue factor b. Nitric oxide d. Thrombin

    c. Tissue factor

  • 46

    What coagulation plasma protein should be assayed when platelets fail to aggregate properly? a. Factor VIII c. Thrombin b. Fibrinogen d. Factor X

    b. Fibrinogen

  • 47

    What is the primary role of vitamin K for the prothrombin group factors? a. Provides a surface on which the proteolytic reactions of the factors occur b. Protects them from inappropriate activation by compounds such as thrombin c. Accelerates the binding of the serine proteases and their cofactors d. Carboxylates the factors to allow calcium binding

    d. Carboxylates the factors to allow calcium binding

  • 48

    What two regulatory proteins form a complex that digests activated factors V and VIII? a. TFPI and Xa b. Antithrombin and protein C c. APC and protein S d. Thrombomodulin and plasmin

    c. APC and protein S

  • 49

    Which of the following coagulation factors is activated by thrombin and mediates the stabilization of the fibrin clot? a. Tissue factor c. Factor IX b. FactorVII d. Factor XIII

    d. Factor XIII

  • 50

    A defect in primary hemostasis (platelet response to an injury) often results in: a. Musculoskeletal bleeding c. Hemarthroses b. Mucosal bleeding d. None of the above

    b. Mucosal bleeding

  • 51

    The clinical presentation of platelet-related bleeding may include all of the following except: a. Bruising c. Gastrointestinal bleeding b. Nosebleeds. d. Bleeding into the joints (hemarthroses)

    d. Bleeding into the joints (hemarthroses)

  • 52

    A defect in GP IIb/IIIa causes: a. Glanzmann thrombasthenia c. Gray platelet syndrome b. Bernard-Soulier syndrome d. Storage pool disease

    a. Glanzmann thrombasthenia

  • 53

    Patients with Bernard-Soulier syndrome have which of the following laboratory test findings? a. Abnormal platelet response to arachidonic acid b. Abnormal platelet response to ristocetin c. Abnormal platelet response to collagen d. Thrombocytosis

    b. Abnormal platelet response to ristocetin

  • 54

    Aspirin ingestion blocks the synthesis of: a. Thromboxane A2 c. Collagen b. Ionized calcium d. ADP

    a. Thromboxane A2

  • 55

    What factor becomes deficient early in liver disease, and what assay does its deficiency prolong? a. Prothrombin deficiency, the PT b. Factor VII deficiency, the PT c. FVIII deficiency, the PTT d. Factor IX deficiency, the PTT

    b. Factor VII deficiency, the PT

  • 56

    Which of the following conditions causes a prolonged thrombin time? a. Antithrombin deficiency c. Hypofibrinogenemia b. Prothrombin deficiency d. Warfarin therapy

    c. Hypofibrinogenemia

  • 57

    What is the most prevalent form of VWD? a. Type1 c. Type 2B b. Type 2A d.Type3

    a. Type1

  • 58

    In what type or subtype of VWD is the RIPA test result positive when ristocetin is used at a concentration of less than 0.5 mg/mL? a. Subtype 2A c. Subtype 2N b. Subtype 2B d. Type 3

    b. Subtype 2B

  • 59

    What is the typical treatment for vitamin K deficiency when the patient is bleeding? a. Vitamin K and plasma b. Vitamin K and four-factor PCC c. Vitamin K and platelet concentrate d. Vitamin K and FVIII concentrate

    b. Vitamin K and four-factor PCC

  • 60

    If a patient has anatomic soft tissue bleeding and poor wound healing, but the PT, PTT, TT, platelet count, and platelet functional assay results are normal, what factor deficiency is possible? a. Fibrinogen c. Factor XII b. Prothrombin d. Factor XIII

    d. Factor XIII

  • 61

    What therapy may be used for a hemophilic boy who is bleeding and who has a high FVIII inhibitor titer? a. rFVIIa c. Cryoprecipitate b. Plasma d. FVIII concentrate

    a. rFVIIa

  • 62

    Which of the following assays is used to distinguish vitamin K deficiency from liver disease? a. PT c. Factor V assay b. Protein C assay d. Factor VII assay

    c. Factor V assay

  • 63

    What is the most common heritable thrombosis risk factor? a. APC resistance (factor V Leiden mutation) b. Prothrombin G20210A mutation c. Antithrombin deficiency d. Protein S deficiency

    a. APC resistance (factor V Leiden mutation)

  • 64

    In most LAC profiles, what test is primary (performed first) because it detects LAC with the least interference? a. Low-phospholipid PTT c. KCT b. DRVVT d. PT

    b. DRVVT

  • 65

    A 1:20 dilution of blood is made with 3% glacial acetic acid as the diluent. The four large corner squares on both sides of the hemacytometer are counted, for a total of 100 cells. What is the total WBC count (x 10^9 /L)? a. 0.25 b. 2.5 c. 5 d. 10

    b. 2.5

  • 66

    The total WBC count is 20 x 10^9/L. Twenty-five NRBCs per 100 WBCs are observed on the peripheral blood film. What is the corrected WBC count (x 10^9/L)? a. 0.8 b. 8 c. 16 d. 19

    c. 16

  • 67

    Which of the following would NOT interfere with the result when hemoglobin determination is performed by the cyanmethemoglobin method? a. Increased lipids c. Lyse-resistant RBCs b. Elevated WBC count d. Fetal hemoglobin

    d. Fetal hemoglobin

  • 68

    A patient has a hemoglobin level of 8.0 g/dL. According to the rule of three, what is the expected range for the HCT? a. 21% to 24% c. 24% to 27% b. 23.7% to 24.3% d. 21% to 27%

    d. 21% to 27%

  • 69

    Given the following values, calculate the RPI: Observed reticulocyte count = 6% HCT = 30% a. 2 c. 4 b.3 d.5

    a. 2

  • 70

    Which of the following would be associated with an elevated ESR value? a. Microcytosis c. Decreased globulins b. Polycythemia d. Inflammation

    d. Inflammation

  • 71

    A laboratory science student consistently makes wedgetechnique blood films that are too long and thin. What change in technique would improve the films? a. Increasing the downward pressure on the pusher slide b. Decreasing the acute angle of the pusher slide c. Placing the drop of blood closer to the center of the slide d. Increasing the acute angle of the pusher slide

    d. Increasing the acute angle of the pusher slide

  • 72

    When a blood film is viewed through the microscope, the RBCs appear redder than normal, the neutrophils are barely visible, and the eosinophils are bright orange. What is the most likely cause? a. The slide was overstained. b. The stain was too alkaline. c. The buffer was too acidic. d. The slide was not rinsed adequately.

    c. The buffer was too acidic

  • 73

    A stained blood film is held up to the light and observed to be bluer than normal. What microscopic abnormality might be expected on this film? a. Rouleaux c. Reactive lymphocytosis b. Spherocytosis d. Toxic granulation

    a. Rouleaux

  • 74

    A laboratorian using the 40x objective lens sees the following numbers of WBCs in 10 fields: 8,4,7,5,4,7,8,6,4,6. Which of the following WBC counts most closely correlates with the estimate? a. 1.5 x 10^9/L c. 11.8 x 10^9/L b. 5.9 x 10^9/L d. 24 x 10^9/L

    c. 11.8 x 10^9/L

  • 75

    A blood film for a patient with a normal RBC count has an average of 10 platelets per oil immersion field. Which of the following values best correlates with the estimate per microliter? a. 20,000 c. 200,000 b. 100,000 d. 400,000

    c. 200,000

  • 76

    A blood film for a very anemic patient with an RBC count of 1.25 x 10^12/L shows an average of seven platelets per oil immersion field. Which of the following values most closely correlates with the estimate per microliter? a. 14,000 c. 140,000 b. 44,000 d. 280,000

    b. 44,000

  • 77

    Which of the following blood film findings indicates EDTAinduced pseudothrombocytopenia? a. The platelets are pushed to the feathered end. b. The platelets are adhering to WBCs. c. No platelets at all are seen on the film. d. The slide has a bluish discoloration when examined macroscopically

    b. The platelets are adhering to WBCs.

  • 78

    Orthogonal light scatter is used to measure: a. Cell volume b. Internal complexity of the cell c. Cellular granularity d. Nuclear density

    b. Internal complexity of the cell

  • 79

    A patient peripheral blood film demonstrates agglutinated RBCs, and the CBC shows an elevated MCHC. What other parameters will be affected by the agglutination of the RBCs? a. MCV will be decreased and RBC count will be increased. b. MCV will be decreased and RBC count will be decreased. c. MCV will be increased and RBC count will be decreased. d. MCV will be increased and RBC count will be increased.

    c. MCV will be increased and RBC count will be decreased.

  • 80

    On the Beckman Coulter instruments, hematocrit is a calculated value. Which of the following directly measured parameters is used in the calculation of this value? a. RDW c. MCV b. Hemoglobin d. MCHC

    c. MCV

  • 81

    What is the most common clinical application of flow cytometry? a. Diagnosis of platelet disorders b. Detection of fetomaternal hemorrhage c. Diagnosis of leukemias and lymphomas d. Differentiation of anemias

    c. Diagnosis of leukemias and lymphomas

  • 82

    Which of the following is true of CD45 antigen? a. It is present on every cell subpopulation in the bone marrow. b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors. c. It is not measured routinely in flow cytometry. d. It may be present on nonhematopoietic cells.

    b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors

  • 83

    Erythroid precursors are characterized by the expression of: a. CD71 b. CD20 c. CD61 d. CD3

    a. CD71

  • 84

    Antigens expressed by B-LL include: a. CD3, CD4, and CD8 b. CD19, CD34, and CD10 c. There are no antigens specific for B-LL. d. Myeloperoxidase

    b. CD19, CD34, and CD10

  • 85

    Which of the following is true of flow cytometric gating? a. It is best defined as selection of a target population for flow cytometric analysis. b. It can be done only at the time of data acquisition. c. It can be done only at the time of final analysis and interpretation of flow cytometric data. d. It is accomplished by adjusting flow rate

    a. It is best defined as selection of a target population for flow cytometric analysis

  • 86

    Mycosis fungoides is characterized by: a. Loss of certain antigens compared with the normal T cell population b. Polyclonal T cell receptor c. Immunophenotype indistinguishable from that of normal T cells d. Expression of CD3 and CD8 antigens

    a. Loss of certain antigens compared with the normal T cell population

  • 87

    Mature granulocytes show the expression of: a. CD15, CD33, and CD34 b. CD15, CD33, and CD41 c. CD15, CD33, and CD13 d. CD15, CD33, and CD7

    c. CD15, CD33, and CD13

  • 88

    What happens if a coagulation specimen collection tube is underfilled? a. The specimen clots and is useless b. The specimen is hemolyzed and is useless c. Clot-based test results are falsely prolonged d. Chromogenic test results are falsely decreased

    c. Clot-based test results are falsely prolonged

  • 89

    What is the reference method for detecting aspirin or clopidogrel resistance? a. Platelet aggregometry c. VerifyNow b. AspirinWorks d. PFA-100

    a. Platelet aggregometry

  • 90

    Except for platelet aggregometry, most coagulation testing must be performed on PPP, which is plasma with a platelet count less than: a. 1000/uL c. 100,000/uL b. 10,000/uL d. 1,000,000/uL

    b. 10,000/uL

  • 91

    You wish to obtain a 5-mL specimen of whole-blood/ anticoagulant mixture. The patient’s hematocrit is 65%. What volume of anticoagulant should you use? a. 0.32 mL c. 0.64 mL b. 0.5 mL d. 0.68 mL

    a. 0.32 mL

  • 92

    You perform whole-blood lumiaggregometry on a specimen from a patient who complains of easy bruising. Aggregation and secretion are diminished when the agonists thrombin, ADP, arachidonic acid, and collagen are used. What is the most likely platelet abnormality? a. Storage pool disorder c. ADP receptor anomaly b. Aspirin-like syndrome d. Glanzmann thrombasthenia

    d. Glanzmann thrombasthenia

  • 93

    What is the reference assay for HIT? a. Enzyme immunoassay c. Platelet lumiaggregometry b. Serotonin release assay d. Washed platelet aggregation

    b. Serotonin release assay

  • 94

    What agonist is used in platelet aggregometry to detect VWD? a. Arachidonic acid c. Collagen b. Ristocetin d. ADP

    b. Ristocetin

  • 95

    Deficiency of which congenital single factor is likely when the PT result is prolonged and the PTT result is normal? a. FactorV c. FactorVIII b. Factor VII d. Prothrombin

    b. Factor VII

  • 96

    A prolonged PT, a low factor VII level, but a normal factor V level are characteristic of an acquired coagulopathy associated with which of the following? a. Vitamin K deficiency c. Liver disease b. Thrombocytopenia d. Hemophilia

    a. Vitamin K deficiency

  • 97

    The patient has deep vein thrombosis. The PTT is prolonged and is not corrected in an immediate mix of patient PPP with an equal part of PNP. What is the presumed condition? a. Factor VIII inhibitor c. Factor VIII deficiency b. Lupus anticoagulant d. Factor V Leiden mutation

    b. Lupus anticoagulant

  • 98

    What condition causes the most pronounced elevation in the result of the quantitative D-dimer assay? a. Deep vein thrombosis c. Paraproteinemia b. Fibrinogen deficiency d. DIC

    d. DIC

  • 99

    When a specimen has been flagged as being icteric by an automated coagulation analyzer, which method would be most susceptible to erroneous results because of the interfering substance? a. Mechanical clot detection b. Immunologic antigen-antibody reaction detection c. Photo-optical clot detection d. Chromogenic end-point detection

    c. Photo-optical clot detection

  • 100

    Which of the following is considered to be an advantage of the mechanical end-point detection methodology? a. It is not affected by lipemia in the test specimen b. It has the ability to provide a graph of clot formation c. It can incorporate multiple wavelengths into a single testing sequence d. It can measure proteins that do not have fibrin formation as the end-point

    a. It is not affected by lipemia in the test specimen